Pharmacogenomics : Social, Ethical, and Clinical Dimensions

個数:

Pharmacogenomics : Social, Ethical, and Clinical Dimensions

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 368 p.
  • 言語 ENG
  • 商品コード 9780471227694
  • DDC分類 615.7

Full Description

Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives  address key elements integral to a comprehensive discussion of this emerging field. This groundbreaking text...



Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics
Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements
Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics

Contents

Foreword (F. Collins). Preface.

PART I: INTRODUCTION: SCIENCE AND SOCIETY.

Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).

Pharmacogenomics:  Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).

The Implications of Population Genetics for Pharmacogenomics (C. Hanis).

PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.

Genome Research and Minorities (H. Greely).

Drug Development Strategies (P. Manasco & T. Arledge).

Drug Development,  Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).

Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally,  et al.).

PART III: CLINICAL APPLICATIONS.

Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky).

Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman).

Medical Liability for Pharmacogenomics (L. Palmer).

The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation  (D. Brushwood).

PART IV: THE SOCIAL DIMENSION.

Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). 

 Pharmacogenomics and the Social Construction of Identity (M. Foster).

Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson).

Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson).

PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).

Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein).

Index.